Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
| ▸ | GRK2 | P25098 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BMP1 | P13497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229260 | 0.80 | ALDH1A1 (0.38) | AKR1B1RORCKMT2AMEN1RAB9A | |
| SCHEMBL7223197 | 0.77 | GAA (0.47) | KMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL7224270 | 0.77 | NR1I2 (0.46) | RORCKMT2AMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL7229122 | 0.77 | CYP3A4 (0.42) | AKR1B1RORCKMT2AMEN1 | |
| SCHEMBL20186989 | 0.77 | AKR1B1 (0.38) | AKR1B1RORCP2RX7KMT2AMEN1 | |
| SCHEMBL7222833 | 0.76 | HPGD (0.47) | RORCKMT2AMEN1 | |
| SCHEMBL7223203 | 0.76 | HPGD (0.39) | RORCKMT2AMEN1 | |
| SCHEMBL7231130 | 0.76 | KMT2A (0.40) | RORCKMT2A | |
| SCHEMBL7222797 | 0.73 | HSD17B2 (0.52) | SMN1; SMN2 | |
| SCHEMBL7224044 | 0.73 | CYP17A1 (0.35) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | COLLONGES FRANCOIS (FR) | 2003-10-30 | — | — | US | disclosed |
| US-6509499-B1 | Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment | MERCK PATENTGESELLSCHAFT MIT (DE) | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203966-A1 | Nitromethylthiobenzene derivatives as aldose reductase inhihibitors | AKR1B1, ALDOA, AKR1C1 | AKR1B1 1/4885RORC 2244/4885P2RX7 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.